| |
| healthcare |
Aster Medical Centre introduces OPD consultancy facility in plastic surgery
December 11, 2019
ASTER Medical Centre, a division of Aster DM Healthcare, one of the largest private healthcare networks in Qatar, has expanded its scope of medical offerings in Qatar. The leading private medical chain has announced the opening of outpatient consultancy in plastic surgery at its Al Hilal branch.
Dr Krishnakumar KS, senior consultant and head of the Department of Plastic Surgery at Aster MIMS, Calicut, will be a visiting consultant there. With nearly 25 years of experience, he is considered one of the most reputed plastic"...
Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019
December 11, 2019
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting that underscore its commitment to advancing treatments for rare bleeding disorders by incorporating real-world data and developing innovative adeno-associated virus (AAV) gene therapies. Understanding Real-World Evidence to Advance Patient-Centric Innovation in Bleeding Disorders Real-world evidence from studies across many of Takeda’s portfolio of treatments for hemophilia demonstrate the cost savings and patient benefits resulting from ongoing personalized treatment. However, in von Willebrand disease, real-world evidence highlights the ongoing unmet clinical need for personalization, as it may enable improved treatment outcomes. Insights presented at ASH include: ADYNOVATE ® [Antihemophilic......
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis
December 11, 2019
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The TOURMALINE-AL1 trial did not meet the first of the two primary endpoints of significant improvement in overall hematologic response, as reported in June 2019. Hematologic responses were seen in 53% versus 51% of patients receiving NINLARO plus dexamethasone versus physician’s choice (odds ratio 1.10 [95% CI 0.60-2.01], p=0.762) as assessed by an Adjudication Committee (AC). The second primary endpoint of......
Sidra Medicine offers reconstructive surgery for children born without ears
December 10, 2019
Microtia is a congenital deformity affecting approximately one out of 4,000 births globally. Children born with the condition have incompletely formed or entirely missing ears.
There is no known cause for microtia and it can affect children on either one or both ears (bilateral microtia). Children with microtia experience varying degrees of hearing loss due to the underdeveloped or missing outer and middle ear regions.
Dr Mitchell Stotland, division chief of Plastic and Craniofacial Surgery, leads Sidra Medicine’s"...
Doha Declaration to promote rights of 1.5 billion people with disabilities worldwide
December 9, 2019
Qatar Foundation for Social Work (QFSW) launched the ‘Doha Declaration’ at the closing ceremony of the Doha International Conference on Disability and Development (DICDD) yesterday. The two-day conference, which has attracted over 1,500 policy-makers and practitioners, took place at the Qatar National Convention Center under the theme: “Leaving No One Behind”. The Doha Declaration on disability and development sets out an"...
Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis
December 9, 2019
Galderma today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational therapy nemolizumab for the treatment of pruritus associated with prurigo nodularis. Prurigo nodularis is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus. It frequently leads to a severe quality of life impairment. "...
MoPH vaccinates over 100,000 people to prevent seasonal flu
December 5, 2019
The Ministry of Public Health (MoPH) has vaccinated 105,000 people against flu, from the launch of the campaign until last week, the ministry has announced.
The ministry, Primary Health Care Corporation (PHCC) and Hamad Medical Corporation (HMC), along with semi-government and private clinics have joined hands to offer free flu vaccine to the public and healthcare workers this year, to ensure easy accessibility for all.
“The most common misconception surrounding the vaccine is its potential to give people"...
UAE Ministry of Health Collaborates with Vocera to Improve Care Team Communication and Optimise Patient Safety
December 5, 2019
Vocera Communications, Inc. (NYSE:VCRA), a recognised leader in clinical communication and workflow solutions, today announced that the Ministry of Health and Prevention of the United Arab Emirates plans to standardise care team communication using Vocera technology. An expected enterprise-wide deployment of the Vocera smartphone app and the new Vocera Smartbadge is part of a strategic alignment aimed at improving care team collaboration, optimising operational efficiency, and elevating patient care and safety. “Our partnership with Vocera and the implementation of the company’s unique solutions represents a breakthrough in our digital transformation,” said Dr. Kalthoom Al Balooshi, Director of Hospitals Department, Ministry of Health and Prevention. “Initial installation of the intelligent hands-free badges and communication platform exceeded our expectations. We......
Gen Re and PAI Health Take Strategic Partnership to Next Level
December 3, 2019
Decades of evidence have proven cardiorespiratory fitness to be a leading predictor of longevity and future health. Yet it is one that has been largely overlooked within insurance customer health profiles. With the signing of the exclusive agreement between leading global reinsurer, Gen Re, and health technology software company, PAI Health, this is set to change. PAI Health is known for its innovation in biometric sensing and algorithm development"...
Swiss luxury, pharmaceuticals companies eye Qatari market
December 2, 2019
Doha: There are more Swiss companies currently exploring opportunities in the Qatari market, and they are expected to bring their products and services to the country’s various industries, including luxury, pharmaceuticals, and other projects related to the upcoming Fifa World Cup 2022, Switzerland’s Ambassador to Qatar Edgar Doerig has said. To date, more than 20 Swiss companies operate in Qatar including Nestle, Sika, and several Swiss"...
|
|
|
|
|